Worth reading
55In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Completion of the last patient's last visit in the Phase 2 clinical trial of MN-001 (tipelukast) for hypertriglyceridemia and fatty liver disease associated with type 2 diabetes
Subject Entity
MediciNova, Inc. (the Company)
Target Locations / Products
MN-001 (tipelukast), clinical trial MN-001-NATG-202
Occurrence26 May 2026
This disclosure05/27/2026
Amount of Impact on Business Performance
No impact on the Company's consolidated results forecast for the fiscal year ending December 2026
Impact on Earnings Forecast
No impact on the Company's consolidated results forecast for the fiscal year ending December 2026
Outlook
Topline data are expected in the third quarter of 2026. The Company will promptly disclose any matters requiring disclosure that arise in the future.
| Item | Details |
|---|---|
| Event name | Completion of the last patient's last visit in the Phase 2 clinical trial of MN-001 (tipelukast) for hypertriglyceridemia and fatty liver disease associated with type 2 diabetes |
| Date of occurrence | 26 May 2026 |
| Subject Entity | MediciNova, Inc. (the Company) |
| Target Locations / Products | MN-001 (tipelukast), clinical trial MN-001-NATG-202 |
| Amount of Impact on Business Performance | No impact on the Company's consolidated results forecast for the fiscal year ending December 2026 |
| Impact on Earnings Forecast | No impact on the Company's consolidated results forecast for the fiscal year ending December 2026 |
| Outlook | Topline data are expected in the third quarter of 2026. The Company will promptly disclose any matters requiring disclosure that arise in the future. |
| Planned follow-up disclosure | Topline data are expected in the third quarter of 2026 |
Items this document does not state (17)
Date recognized / date notice receivedCauseAccounting period in which recognizedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the change
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.